Barclays reiterated their buy rating on shares of Agilent Technologies (NYSE:A) in a report issued on Monday, January 8th. They currently have a $74.00 price target on the medical research company’s stock.
Several other equities analysts have also recently weighed in on the stock. Robert W. Baird reiterated a buy rating and set a $70.00 price objective on shares of Agilent Technologies in a research report on Friday, October 20th. Zacks Investment Research upgraded shares of Agilent Technologies from a hold rating to a buy rating and set a $74.00 price objective on the stock in a research report on Tuesday, October 10th. ValuEngine lowered shares of Agilent Technologies from a buy rating to a hold rating in a research note on Friday, December 1st. Deutsche Bank set a $75.00 target price on shares of Agilent Technologies and gave the company a buy rating in a research note on Tuesday, November 21st. Finally, Morgan Stanley reissued an overweight rating on shares of Agilent Technologies in a research note on Tuesday, November 14th. Six research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The stock presently has an average rating of Buy and an average price target of $69.25.
Agilent Technologies (NYSE:A) traded down $0.60 on Monday, hitting $72.83. The stock had a trading volume of 1,978,774 shares, compared to its average volume of 1,660,000. Agilent Technologies has a 52 week low of $48.47 and a 52 week high of $75.00. The company has a market capitalization of $23,440.00, a PE ratio of 34.85, a PEG ratio of 2.20 and a beta of 1.28. The company has a debt-to-equity ratio of 0.37, a quick ratio of 2.85 and a current ratio of 3.30.
Agilent Technologies (NYSE:A) last announced its earnings results on Monday, November 20th. The medical research company reported $0.67 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.62 by $0.05. The firm had revenue of $1.19 billion for the quarter, compared to analysts’ expectations of $1.17 billion. Agilent Technologies had a return on equity of 16.95% and a net margin of 15.30%. The firm’s quarterly revenue was up 7.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.59 earnings per share. equities analysts forecast that Agilent Technologies will post 2.58 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which was paid on Wednesday, January 24th. Stockholders of record on Tuesday, January 2nd were issued a dividend of $0.149 per share. This is an increase from Agilent Technologies’s previous quarterly dividend of $0.13. The ex-dividend date was Friday, December 29th. This represents a $0.60 annualized dividend and a dividend yield of 0.82%. Agilent Technologies’s payout ratio is presently 28.71%.
In other Agilent Technologies news, VP Mark Doak sold 4,154 shares of the company’s stock in a transaction dated Tuesday, December 5th. The shares were sold at an average price of $67.00, for a total transaction of $278,318.00. Following the sale, the vice president now directly owns 68,270 shares of the company’s stock, valued at $4,574,090. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Michael R. Mcmullen sold 21,850 shares of the company’s stock in a transaction dated Monday, January 29th. The stock was sold at an average price of $75.00, for a total transaction of $1,638,750.00. Following the sale, the chief executive officer now directly owns 324,687 shares in the company, valued at $24,351,525. The disclosure for this sale can be found here. In the last three months, insiders sold 219,991 shares of company stock worth $15,468,795.
Several hedge funds have recently made changes to their positions in the company. BlackRock Inc. lifted its position in shares of Agilent Technologies by 1.2% during the second quarter. BlackRock Inc. now owns 23,392,338 shares of the medical research company’s stock worth $1,387,400,000 after purchasing an additional 273,119 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Agilent Technologies by 3.0% during the second quarter. Vanguard Group Inc. now owns 22,093,669 shares of the medical research company’s stock worth $1,310,374,000 after purchasing an additional 637,698 shares in the last quarter. Victory Capital Management Inc. lifted its position in shares of Agilent Technologies by 8.2% during the third quarter. Victory Capital Management Inc. now owns 3,330,488 shares of the medical research company’s stock worth $213,817,000 after purchasing an additional 253,250 shares in the last quarter. Wells Fargo & Company MN lifted its position in shares of Agilent Technologies by 27.6% during the third quarter. Wells Fargo & Company MN now owns 2,184,502 shares of the medical research company’s stock worth $140,244,000 after purchasing an additional 473,047 shares in the last quarter. Finally, Impax Asset Management LTD lifted its position in shares of Agilent Technologies by 14.9% during the third quarter. Impax Asset Management LTD now owns 2,106,322 shares of the medical research company’s stock worth $135,226,000 after purchasing an additional 272,571 shares in the last quarter.
ILLEGAL ACTIVITY NOTICE: “Barclays Reiterates “Buy” Rating for Agilent Technologies (A)” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of international copyright & trademark laws. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/02/01/agilent-technologies-a-rating-reiterated-by-barclays.html.
About Agilent Technologies
Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.
Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.